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Abstract
Introduction: The acute gout flare results from a localised self-limiting innate immune response to monosodium
urate (MSU) crystals deposited in joints in hyperuricaemic individuals. Activation of the caspase recruitment
domain-containing protein 8 (CARD8) NOD-like receptor pyrin-containing 3 (NLRP3) inflammasome by MSU crystals
and production of mature interleukin-1β (IL-1β) is central to acute gouty arthritis. However very little is known
about genetic control of the innate immune response involved in acute gouty arthritis. Therefore our aim was to
test functional single nucleotide polymorphism (SNP) variants in the toll-like receptor (TLR)-inflammasome-IL-1β axis
for association with gout.
Methods: 1,494 gout cases of European and 863 gout cases of New Zealand (NZ) Polynesian (Māori and Pacific
Island) ancestry were included. Gout was diagnosed by the 1977 ARA gout classification criteria. There were 1,030
Polynesian controls and 10,942 European controls including from the publicly-available Atherosclerosis Risk in
Communities (ARIC) and Framingham Heart (FHS) studies. The ten SNPs were either genotyped by Sequenom
MassArray or by Affymetrix SNP array or imputed in the ARIC and FHS datasets. Allelic association was done by
logistic regression adjusting by age and sex with European and Polynesian data combined by meta-analysis.
Sample sets were pooled for multiplicative interaction analysis, which was also adjusted by sample set.
Results: Eleven SNPs were tested in the TLR2, CD14, IL1B, CARD8, NLRP3, MYD88, P2RX7, DAPK1 and TNXIP genes.
Nominally significant (P < 0.05) associations with gout were detected at CARD8 rs2043211 (OR = 1.12, P = 0.007), IL1B
rs1143623 (OR = 1.10, P = 0.020) and CD14 rs2569190 (OR = 1.08; P = 0.036). There was significant multiplicative
interaction between CARD8 and IL1B (P = 0.005), with the IL1B risk genotype amplifying the risk effect of CARD8.
Conclusion: There is evidence for association of gout with functional variants in CARD8, IL1B and CD14. The
gout-associated allele of IL1B increases expression of IL-1β – the multiplicative interaction with CARD8 would be
consistent with a synergy of greater inflammasome activity (resulting from reduced CARD8) combined with higher
levels of pre-IL-1β expression leading to increased production of mature IL-1β in gout.
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Introduction
The immediate cause of gout is the deposition of mono-
sodium urate (MSU) crystals in and around body tissues,
particularly joints [1]. Initially, these deposits trigger a
localised and self-limiting inflammatory response (acute
gouty arthritis), which becomes increasingly frequent
and severe, involving multiple joints and associated with
fever. Monosodium urate crystals form under hyperuri-
caemic conditions when serum urate levels exceed the
physiological saturation level (approximately 6.8 mg/dL;
approximately 0.41 mM). The most significant biological
cause of hyperuricaemia is relatively low renal clearance
of uric acid [2, 3]. This is consistent with findings from
genome-wide association studies in which 28 loci associ-
ated with serum urate levels have been identified, some
of which are in genes involved in renal uric acid hand-
ling [4, 5]. Predictably most, but not all, of the 28 loci
have been associated with gout [4, 6].
Although hyperuricaemia is a prerequisite for MSU
formation, only a relatively small proportion of indi-
viduals with hyperuricaemia develop gout [7]. This
indicates that beside genetic variants associated with
urate metabolism and excretion, other factors contribute
to the pathogenesis of gout. MSU crystals play an im-
portant role in activation of the innate immune system
[8] and the recognition of gout as an auto-inflammatory
disorder is consistent with the results of functional stud-
ies [9, 10]. Variations within genes of the innate immune
system may therefore determine whether MSU crystals
trigger an inflammatory reaction in susceptible indi-
viduals, leading to acute gout; while in others, no inflam-
mation is elicited. Genetic variants that influence the
activation and function of the NOD-like Receptor Pyrin
containing 3 (NLRP3) inflammasome are candidate
genes in this context [11]. The multi-protein inflamma-
some complex, comprising the NLRP3 polypeptide, ASC
or PYCARD (apoptosis-associated speck-like protein
containing a CARD) and caspase-1 [12] forms when
monocytes and macrophages encounter damaged and
pathogen-associated molecular pattern proteins (DAMPs
and PAMP; e.g., bacterial lipopolysaccharide or MSU
crystals) and leads to activation of caspase-1. Active
caspase-1 processes the pro-interleukin (IL)-1β to the
mature pro-inflammatory cytokine IL-1β that is then
secreted [12].
CARD8 (also known as TUCAN or Cardinal) is a pro-
tein with a caspase-domain that interacts with caspase-1
and inhibits its activation [13] and also with a FIIND do-
main that binds to NLRP3 preventing its recruitment into
the active inflammasome complex [14, 15]. Genetic asso-
ciations between variants of CARD8 and autoimmune dis-
eases have been previously reported (reviewed in [16]).
The T allele of CARD8 rs2043211 (C10X) has been asso-
ciated with increased risk of gout in Chinese [17], and
rs2149356 in toll-like receptor 4 (TLR4), a receptor func-
tionally implicated in MSU-stimulated inflammation [18],
has also been associated with serum IL-1β levels and the
risk of gout in Han Chinese [19]. However, using a haplo-
type tagging approach, there is no evidence of association
between NLRP3 and gout in Chinese [20].1
Our aim was to extend the findings from the Han
Chinese population [17] and to test genetic variants in-
fluencing inflammasome function for association with
gout in other population groups. Eleven functional vari-
ants were tested in eight genes involved in the MSU
crystal-mediated activation of the NLRP3-inflammasome
and production of mature IL-1β for association with
gout in people of European and New Zealand (NZ)
Polynesian (Māori and Pacific Island) ancestry. The
prevalence of gout in the NZ Polynesian population is
6–8 % (compared to 3 % in NZ European), exhibiting
the highest prevalence worldwide [21, 22].
Methods
Participants, ethics and consent
The study was carried out on sample sets comprising: a
NZ Polynesian sample set consisting of 1,893 individuals
of Samoan, Tongan, Niuean, Cook Island Māori and NZ
Māori descent (Table 1; 863 cases and 1,030 controls);
and a sample set consisting of 1,684 cases of European
ancestry (957 recruited from NZ and Australia and 727
recruited from Europe (‘Eurogout’) [23]) and 882 NZ
European controls. All people with gout met the 1977
preliminary American Rheumatism Association classifi-
cation criteria for gout [24]. New Zealand gout cases
were recruited from the Auckland and Christchurch re-
gions of NZ, Australian gout cases from an outpatient
clinic in Adelaide, Australian private practice rheumatol-
ogists and from a previously reported pharmacogenetic
study [25]. European gout cases were recruited from
outpatient clinics in Edinburgh, Lausanne, Dresden,
Arnhem and Nijmegen. The NZ controls did not have
any self-reported history of arthritis, were >17 years of age
and were convenience sampled from the Auckland,
Christchurch and Otago regions of NZ. The New Zealand
Multi-Region Ethics Committee (MEC/105/10/130) and
these institutional committees in Europe and Australia
granted ethical approval: Research Ethics Committee,
University of New South Wales; Ethikkommission,
Technische Universität Dresden (EK 8012012); South East
Scotland Research Ethics Committee (04/S1102/41);
Commission Cantonale (VD) D'éthique de la Recherche
sur l'être Humain, Université de Lausanne; Commissie
Mensgebonden Onderzoek regio Arnhem Nijmegen. All
subjects gave written and informed consent.
Control subjects of European ancestry, who had been
genotyped genome-wide, were also included from the
Atherosclerosis Risk in Communities (ARIC) study
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(n = 6,989) and the Framingham Heart Study (FHS;
n = 3,131). Participants with self-reported gout were ex-
cluded. The sample sets were also screened to remove all
but one representative of any closely related family group-
ing (full/half siblings and parent/child duos and trios).
The ARIC study and FHS analyses (project #834) were
approved by the relevant Database of Genotype and
Phenotype (dbGaP; [26]) Data Access Committees.
Genotyping and imputation
A Sequenom MassARRAY System was used for genotyp-
ing the 4,269 individuals without genome-wide genoytpe
data available as previously described [27]. Publicly avail-
able genome-wide genotype data from ARIC and FHS
were imputed as required to obtain genotypes from the
eleven selected SNPs. Imputations were carried out by
IMPUTE V2.2 software based on the combined 1000
Genomes V3 population reference set. Individuals and
SNPs with a call rate of <0.98 were excluded from analysis,
as were monomorphic markers and those with a minor
allele frequency of <0.01, and a post-imputation quality
threshold of 0.30 was used. Imputations were successful
for all eleven SNPs and all imputed SNPs were in Hardy-
Weinberg equilibrium (P >0.005) with the exception of
NLRP3 rs7512998 in ARIC (PHWE = 1.3 × 10
-27) - these
data were excluded from analysis. Where necessary,
imputed data were strand-adjusted to match the strand
interrogated by the Sequenom data prior to analysis.
Association testing
Allelic association analysis was carried out using R soft-
ware and adjusting for age and sex. For Polynesian sam-
ples, a genetically estimated proportion of Polynesian
ancestry, calculated as previously described [27], was
included as an additional covariate. All odds ratios are
reported relative to the minor allele present in the geno-
typed NZ European control sample set. Meta-analyses
were carried out using METAL [28] with weighting
based on standard error and log (odds ratio (OR)) as the
effect variable. Significant association was declared if P
was <0.05 in the European and Polynesian meta-analysis.
No correction for multiple testing was applied because
there is prior functional evidence for each variant tested.
Power curves are shown in Additional file 1. The
Polynesian sample set was adequately powered to detect
common effects (minor allele frequency (MAF) >0.1) of
OR ≥1.4, whereas the European sample set was ad-
equately powered to detect common effects of MAF >0.2
at OR >1.2 and stronger effects (OR >1.4) at lower MAF
(>0.05).
Interaction analysis
As reviewed by Cordell [29] there are a number of ways
to test for interaction or a departure from additivity. We
used Stata 13.1 software to carry out logistic regression
analysis comparing the disease risk for heterozygosity
and minor allele homozygosity for each locus individu-
ally and in combination. Previously we reported a large
allele frequency difference at ABCG2 rs2231142 and het-
erogeneity in association with gout between Eastern (EP)
and Western (WP) Polynesian sample sets [30]. Simi-
larly, there are differences in allele and genotype fre-
quencies between the two groups (Additional file 2), and
heterogeneity will be magnified in combined genotypes.
Therefore, in the interaction analysis adjustment was
made separately for EP and WP, along with European data.
An interaction term was included and a P value <0.017
(Bonferroni-adjusted for number of interaction analyses
Table 1 Age, sex and serum urate details of studied sample sets
Sample set Male, Female,
number (%) Average agea
(range)
Average serum urate
mmol/Lb (range)
number (%) Average agea
(range)
Average serum urate
mmol/Lb (range)
Eastern Polynesian Gout 365 (76.5) 37.8 (8–78) 0.47 (0.11–0.98) 112 (23.5) 51.0 (10–81) 0.45 (0.10–0.74)
Control 268 (38.0) 42.5 (17–85) 0.41 (0.13–0.67) 437 (62.0) 46.5 (17–88) 0.34 (0.15–0.58)
Western Polynesian Gout 341 (91.9) 35.1 (11–75) 0.49 (0.17–0.84) 30 (8.1) 43.8 (14–80) 0.49 (0.22–0.72)
Control 175 (56.8) 38.3 (18–72) 0.42 (0.19–0.73) 133 (43.2) 41.2 (17–58) 0.35 (0.14–0.67)
Australasian Gout 794 (82.7) 45.9 (5–92) 0.42 (0.11–0.80) 163 (17.3) 62.6 (20–90) 0.39 (0.13–0.74)
Control 465 (53.0) 52.3 (18–87) 0.38 ( 0.18–0.77) 412 (47.0) 44.9 (17–95) 0.27 (0.13–0.59)
Eurogout Gout 628 (86.4) 44.9 (16–83) 0.42 (0.09–0.92) 99 (13.6) 57.5 (30–92) 0.47 (0.13–0.88)
FHS Control 1681 (53.7) 40.8 (19–69) 0.38 (0.13–0.67) 1450 (46.3) 43.9 (23–58) 0.26 (0.07–0.54)
ARIC Control 3172 (45.4) 54.3 (44–66) 0.39 (0.08–0.71) 3817 (54.6) 55.6 (45–65) 0.31 (0.03–0.66)
All European Gout 1422 (84.5) 45.5 (5–92) 0.42 0.09–0.92) 262 (15.5) 60.9 (20–92) 0.42 (0.13–0.88)
Control 5318 (61.9) 50.0 (18–87) 0.38 (0.08–0.77) 5679 (38.1) 49.9 (17–95) 0.29 (0.03–0.66)
aAge at diagnosis for gout cases, at recruitment for controls. bSerum urate levels at recruitment. Data presented for individuals for whom sex information
was available
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performed) was considered to indicate significant multi-
plicative interaction between genetic variants.
Results
Eleven functional genetic variants in NLRP3, CARD8,
IL1B, DAPK1, TXNIP, TLR2, P2XR7, MYD88 and CD14
were selected from the literature (Table 2) and geno-
typed; genotype distributions are presented in Additional
file 2. There was nominal allelic association (P <0.05) for
three variants in the combined European and Polynesian
analysis (Table 3) - IL1B, CARD8 and CD14 (OR = 1.10,
1.12 and 1.08, respectively). CARD8 rs2043211 was also
associated with gout in Europeans (OR = 1.11).
Because of reported interactions between NLRP3 and
CARD8 in other auto-inflammatory conditions [30, 31],
and the biological interaction between the inflammasome
and IL-1β we tested for pairwise multiplicative interaction
between NLRP3/CARD8, NLRP3/IL1B and CARD8/IL1B
(Table 4), using only rs10754558 of NLRP3 owing to the
low MAF of rs35829419 in both Europeans and Polynesians
and the low MAF of rs7512998 in Polynesians. There
was evidence for interaction between CARD8 and IL1B
(P = 0.005, Pc = 0.015), driven by amplification of the risk
conferred by the CARD8 rs2043211 Tallele in the presence
of the rs1143623 IL1B minor allele homozygous (GG)
genotype. Nominally significant interaction between
NLRP3/IL1B (PNominal = 0.048) was also observed, although
this was not significant after adjustment for multiple test-
ing (Pc = 0.144).
Discussion
TLR signalling via the NLRP3 inflammasome has been
implicated in gout susceptibility and pathology in vivo and
in vitro [10]; for example, MSU uptake and IL-1β produc-
tion by bone marrow-derived macrophages derived from
TLR2, TLR4 or Myd88 knockout mice is significantly re-
duced, as is neutrophil influx, in response to subcutaneous
injection of MSU in whole animals [18]. To further eluci-
date the role of the TLR-inflammasome-IL-1β cascade in
gout pathogenesis, eleven candidate genetic variants that
functionally impact on this pathway (reviewed in [10])
were tested for association with gout in a sample set of
2,357 cases, adequately powered to detect association with
common variants having an effect size of odds ratio 1.4 or
Table 2 Eleven genetic variants in NLRP3, CARD8, DAPK1, TXNIP, TLR2, P2XR7, MYD88 and CD14 were selected from the literature
SNP (gene) Functional information Association with auto-inflammatory phenotype
rs10754558 (NLRP3) NLRP3 is a component of
the NALP3 inflammasome.
Variant influences transcription (G > C) [46] None
rs35829419 (NLRP3) Gain-of-function, with CARD8pC10X
identified in arthritic patient with abnormally
high IL-1 [47, 48]
Minor allele protective against celiac disease
in a small study [49]
rs7512998 (NLRP3) None Refer endnote 1 [20]
rs2043211 (CARD8). CARD8 is a negative
regulator of IL-1β secretion
C10X encodes a truncated protein that does
not abrogate NFkB transcription [50]. Can be
evaded by alternative splicing [51]. Identified
as F102I in dbSNP
Interacts with NLRP3 rs35892419 in risk of
Crohn’s disease [31]. Associated with disease
severity in RA [50]
rs1143623 (IL1B). IL-1β is a pro-inflammatory
cytokine produced by activated NALP3
inflammasome
Promoter variant influences IL6 levels after
fatty-acid rich meals [38] and IL-1β levels in
small Crohn’s disease study [52]
G allele associated with protection from
RA [53]
rs4696480 (TLR2). Toll-like receptor involved
in NALP3 inflammasome activation
Within binding site for the THP-1-derived
nuclear protein, influences reporter
expression [54]
None
rs2569190 (CD14). CD14 is an adaptor
molecule used by TLR2
Rs2569190 T allele alters transcriptional
activity [42, 43]
On meta-analysis is associated with Crohn’s
disease [55] and asthma [56]
rs6853 (MYD88). MYD88 is a transducer in the
TLR signalling pathway
A allele creates potential miR-562b binding
site [57]
None
rs17525809 (P2RX7). Purine receptor involved
in a pathway of NALP3 activation via
amyloid A
Missense variant (Val > Ala), T allele reduces
activity [58]
None
rs4878104 (DAPK1). DAPK1 (death associated
kinase) is involved in NALP3 assembly.
Exhibits allelic specific differences in
expression [59]
None
rs7212 (TXNIP). TXNIP is thioredoxin-interacting
protein required for full inflammasome
activation
Increased mRNA expression in smooth
muscle cells with G allele [60]
None
NALP3 NACHT, LRR and PYD domains containing protein 3, CARD8 caspase recruitment domain-containing protein 8, RA rheumatoid arthritis, TLR toll-like receptor,
NLRP3 NOD-like Receptor Pyrin containing 3
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greater (Additional file 1). As discussed below, the nom-
inal evidence for association between gout and CD14,
CARD8 and IL1B, and the multiplicative interaction be-
tween CARD8 and IL1B in determining the risk of gout,
support the considerable evidence that TLR-mediated ac-
tivation of the inflammasome and subsequent release of
active IL-1β is a central causal pathogenic pathway of
gout [10, 32].
Variants rs2043211 (CARD8), rs1143623 (IL1B) and
rs2569190 (CD14), which were associated with gout, are
functional variations in genes directly involved in the
NLRP3 signaling pathway, and as such are likely to
represent genuine disease-susceptibility loci. CARD8 is
an adaptor protein that regulates IL-1β secretion by
inhibiting NFKβ signaling (required for the expression of
pro-IL-1β) and/or interacting with caspase 1 or NLRP3
to inhibit the generation of active IL-1β from inactive
pro-IL-1β [13, 15]. The effect size of CARD8 SNP
rs2043211 was consistent between the European and
NZ Polynesian samples sets (OR = 1.11, P = 0.023 and
OR = 1.15, P = 0.078, respectively; combined OR = 1.12,
P = 0.007) and the Chinese sample set reported by Chen
et al. (OR = 1.19, P = 0.08) [17]. Collectively our results
and the study by Chen et al. [17] do suggest that the
association of the minor allele of rs2043211 with gout is
not a false positive one. SNP rs2043211 encodes a mis-
sense protein variation (C10X or F52I depending on tran-
script, [33]) with the minor allele increasing the risk of
gout. Although the functional effect of this variation has
not been specifically evaluated, the SNP is within an ex-
pression quantitative trait locus peak and carriage of the
minor allele is associated with decreased CARD8 ex-
pression [34]. It has been inconsistently associated with
other auto-inflammatory phenotypes, with some evidence
for epistatic interaction with NLRP3 rs35829419 in
determining risk of inflammatory bowel disease and ab-
dominal aortic aneurysms [31, 35]. However, we found no
evidence of interaction between NLRP3 and CARD8 in
determining risk of gout (Table 4) (although we did not
specifically analyse rs35829419), and it has also been sug-
gested that under certain conditions, ASC-dependent IL1-
β production in response to MSU stimulation can occur in
the absence of NLRP3 [36].
IL1B SNP rs1143623 is within a promoter GATA tran-
scription factor family binding site. Although the minor
allele exhibits enhanced protein-binding [37] and de-
creased expression in vitro and in vivo, the effect of this
variation seems to be influenced both by the wider pro-
moter haplotype [38–40], and the identity of the stimu-
latory signal; the minor allele shows increased rather
than decreased expression in vitro in response to TNF-α
[40], and has also been associated with increased post-
prandial triglyceride and IL6 (an effector of IL-1β) levels
[41]. The minor allele is over-represented in gout cases
compared to controls (OR = 1.10, P = 0.020). If this is
replicated it would be consistent with an etiological role
for increased IL1B expression in gout. There was
evidence of multiplicative interaction with CARD8
rs2043211 in which the IL1B rs1143623 minor (risk)
allele homozygous genotype appeared to amplify the
effect of the minor allele of rs2043211. This would be
consistent with a synergy of greater inflammasome
activity (resulting from reduced CARD8) combined with
higher levels of pre-IL-1β expression leading to in-
creased production of mature IL-1β in gout.
The final variation nominally associated with gout was
CD14 SNP rs2569190. This SNP is in the 5’UTR of one
of the two CD14 splice variants, with the minor allele
(that increases risk of gout) increasing expression in
monocytes by decreasing affinity for the inhibitory Sp3
Table 3 Analysis of associations between the minor alleles of the eleven variants and gout
European Polynesian Meta-analysis
Gene, SNP, minor allele MAF case MAF control OR (95 % CI) P MAF case MAF control OR (95 % CI) P OR (StdErr) P
NLRP3, rs10754558, G 0.408 0.418 0.95 (0.87–1.04) 0.25 0.459 0.434 1.07 (0.91–1.24) 0.42 0.96 (0.036) 0.44
NLRP3, rs35829419, A 0.046 0.047 0.88 (0.71–1.07) 0.20 0.004 0.012 0.58 (0.20–1.53) 0.29 0.87 (0.098) 0.15
NLRP3, rs7512998, C 0.170 0.160 1.09 (0.94–1.27) 0.25 0.033 0.045 1.03 (0.67–1.60) 0.88 1.08 (0.075) 0.29
CARD8, rs2043211, T 0.338 0.321 1.11 (1.01–1.22) 0.023 0.499 0.439 1.15 (0.98–1.35) 0.078 1.12 (0.042) 0.007
IL1B, rs1143623, G 0.278 0.266 1.09 (0.99–1.20) 0.066 0.532 0.481 1.14 (0.98–1.33) 0.098 1.10 (0.042) 0.020
TLR2, rs4696480, T 0.495 0.499 1.02 (0.93–1.11) 0.68 0.482 0.490 0.98 (0.84–1.15) 0.84 1.01 (0.036) 0.74
CD14, rs2569190, A 0.496 0.475 1.08 (0.99–1.18) 0.070 0.576 0.542 1.07 (0.92–1.26) 0.37 1.08 (0.036) 0.036
MYD88, rs6853, G 0.112 0.120 0.88 (0.77–1.00) 0.059 0.026 0.028 1.18 (0.71–1.98) 0.52 0.90 (0.068) 0.11
P2RX7, rs17525809, C 0.071 0.068 1.09 (0.92–1.29) 0.30 0.056 0.068 0.78 (0.56–1.08) 0.13 1.01 (0.080) 0.87
DAPK1, rs4878104, T 0.358 0.353 1.02 (0.93–1.11) 0.72 0.701 0.622 1.13 (0.96–1.34) 0.14 1.05 (0.044) 0.32
TNXIP, rs7212, G 0.050 0.041 1.27 (1.04–1.55) 0.020 0.191 0.175 1.00 (0.82–1.22) 0.98 1.13 (0.071) 0.091
SNP single nucleotide polymorphism, MAF minor allele frequency, OR odds ratio, StdErr standard error
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transcription factor [42], enhancing the loading of RNA
polymerase II [43] and is associated with increased
soluble CD14 levels in healthy individuals [44, 45].
Membrane-bound CD14 forms functional complexes
with TLR2 or TLR4 and leukocyte β2-integrins, which
could mediate TLR dimerization and optimize the innate
immune response to MSU crystals [10].
Conclusions
In conclusion we provide evidence for association of gout
with functional innate immune system variants in CARD8,
IL1B and CD14, and multiplicative interaction between
IL1B and CARD8. The findings involving IL1B are consist-
ent with genetically determined levels of IL-1β being im-
portant in gout.
Endnote
1Note that the Meng et al paper [20] reported positive
association with single nucleotide polymorphism (SNP)
rs7512998, however the P value for this SNP had been
incorrectly calculated - the true P value for rs7512998
was 0.43 - as reported in a corrigendum [61].
Table 4 Interaction analysis: genotype combinations of CARD8 rs2043211 and NLRP3 rs10754558, CARD8 rs2043211 and IL1B
rs1143623, and NLRP3 rs10754558 and IL1B rs1143623
Number (%)
Combination Cases Controls OR (95 % CI) Pa
rs10754558- rs2043211 (NLRP3-CARD8)
CC/AA 318 (0.127) 1,862 (0.155) 1.00
CC/AT 376 (0.150) 1,722 (0.144) 1.17 (0.96–1.42) 0.11
CC/TT 133 (0.053) 476 (0.040) 1.55 (1.18–2.04) 0.001
CG/AA 450 (0.180) 2,606 (0.217) 0.94 (0.78–1.13) 0.53
CG/AT 583 (0.233) 2,565 (0.214) 1.16 (0.97–1.38) 0.11
CG/TT 186 (0.074) 635 (0.053) 1.45 (1.11–1.81) 0.006
GG/AA 172 (0.069) 964 (0.080) 0.95 (0.75–1.20) 0.65
GG/AT 206 (0.082) 905 (0.076) 1.22 (0.97–1.54) 0.085
GG/TT 80 (0.032) 258 (0.022) 1.71 (1.23–2.39) 0.002
rs1143623-rs2043211 (IL1B-CARD8)
CC/AA 430 (0.174) 2,821 (0.236) 1.00
CC/AT 488 (0.197) 2,740 (0.229) 1.13 (0.96–1.32) 0.16
CC/TT 136 (0.055) 644 (0.054) 1.26 (0.99–1.62) 0.066
CG/AA 390 (0.157) 2,182 (0.182) 1.10 (0.92–1.31) 0.28
CG/AT 495 (0.200) 1,979 (0.165) 1.48 (1.25–1.75) 4.3 × 10−6
CG/TT 162 (0.065) 575 (0.048) 1.74 (1.36–2.22) 8.7 × 10−6
GG/AA 112 (0.045) 425 (0.036) 1.33 (1.00–1.77) 0.049
GG/AT 166 (0.067) 465 (0.039) 1.61 (1.25–2.07) 2.0 × 10−4
GG/TT 100 (0.040) 147 (0.012) 3.77 (2.65–5.34) <1.0 × 10−6
rs10754558- rs1143623 (NLRP3-IL1B)
CC/CC 352 (0.141) 2,147 (0.179) 1.00
CC/CG 346 (0.139) 1,574 (0.131) 1.32 (1.09–1.60) 0.005
CC/GG 128 (0.051) 340 (0.028) 2.09 (1.57–2.78) <1.0 × 10−6
CG/CC 497 (0.200) 2,963 (0.247) 1.00 (0.84–1.19) 1.00
CG/CG 529 (0.212) 2,312 (0.193) 1.30 (1.09–1.54) 0.004
CG/GG 184 (0.074) 524 (0.044) 1.43 (1.11–1.85) 0.005
GG/CC 209 (0.084) 1,099 (0.092) 1.22 (0.98–1.52) 0.072
GG/CG 179 (0.072) 851 (0.071) 1.14 (0.90–1.44) 0.272
GG/GG 66 (0.026) 173 (0.014) 1.70 (1.17–2.48) 0.006
aPInteraction was 0.91for CARD8/NLRP3, 0.005 for CARD8/IL1B, and 0.048 for NLRP3/IL1B. OR odds ratio
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